Parents of man who died in Colorado jail say nurses, deputies ignored his pleas for 15 hours
The lawsuit blames them, local government officials and Southern Health Partners for failing to stop the death of Daniel Foard in 2023 by taking him to the hospital. Foard, 32, was a cook at a brewpub and user of fentanyl who was arrested for failing to appear in court. After being segregated and monitored for withdrawal from the synthetic opioid, he began vomiting and complained of stomach pain after being put in a regular jail cell, it said.
The lawsuit alleges Southern Health Partners — the Tennessee-based company they contracted with to provide health care at the La Plata County jail — has tried to maximize its profits at the jail by only having one nurse on duty at a time, leaving it to medically untrained deputies to monitor sick inmates. The company holds hundred of contracts at jails around the country and the lawsuit alleges that is has been involved in lawsuits related to the deaths of at least five other jail inmates nationally.
The company's lawyer, Shira Crittendon, said she had not seen the lawsuit and declined to comment on it.
The sheriff's office referred questions about the the lawsuit to a county spokesperson. In a statement, the county said it had not analyzed the allegations in the lawsuit and does not comment publicly on active litigation.
Autopsy found Foard died because of an ulcer
Foard was found dead in the jail on Aug. 17, 2023, six days after he was arrested.
An autopsy found Foard died as a result of a hole created by an ulcer in his small intestine, which caused inflammation of the tissue lining his abdomen. Such ulcers can let food and digestive juices leak out of the body's digestive tract.
Fentanyl, a synthetic opioid, was found in Foard's blood but the autopsy report did not name that as a cause of his death. Dr. Michael Arnall ruled Foard's death was due to natural causes.
On Aug. 15, 2023, even though Foard had collapsed several times and had trouble standing, he was moved out of an area where he could be more easily observed for problems with his withdrawal and put into a regular jail cell, staggering as we went, the lawsuit said. The day nurse ignored a deputy's concern that he was very unstable, according to the lawsuit brought by lawyers Dan Weiss, Anna Holland Edwards, John Holland and Erica Grossman.
After a deputy delivering breakfast on Aug. 16, 2023 saw that Foard repeatedly fell while trying to get his tray, the jail's day nurse came to check on him, it said. She recorded that Foard reported he had sharp, shooting pain that was a '10' on a scale of one to 10, but she did not call for a doctor or send him to the hospital, it said.
The nurse moved Foard to an empty cell where he could be monitored but didn't tell deputies what he was being monitored for and didn't order any follow up care or check on him, it said. He vomited all day and was moved to another cell and then a third because they had all become so messy with vomit, it said. Surveillance video showed him crawling to the final cell, where it said he continuously called out for help and yelled that he needed to go to a hospital, saying he was vomiting blood. The lawsuit claims that no one responded to his pleas but one deputy could be heard on surveillance video telling him to 'try to hit that drain' with his vomit to keep the cell from becoming dirty.
Another nurse, working the evening shift, only walked by his cell and glanced inside, but did not assess him or provide care as he was pleading for help, the lawsuit said. When she did enter his cell around 10 p.m., Foard was dead, it said. She told state investigators that vomiting was normal for people withdrawing from fentanyl.
State authorities investigated Foard's death
The day shift nurse later told a state investigator that it was not unusual that Foard would not have had his vital signs checked for 12 hours because of the number of inmates the jail's nurses need to provide care, according to a report from an investigation by the Colorado Bureau of Investigations. She also said she didn't think there was anything different she could have done based on Foard's symptoms.
The bureau's findings were forwarded to the 6th District Attorney's Office, which would decide whether any criminal charges were warranted in connection with Foard's death. It's not known whether the office decided to pursue any charges. A telephone message and email sent to District Attorney Sean Murray were not immediately returned.
In a statement, Jim Foard and Susan Gizinski said they want everyone to know about their son's ordeal both to hold those they say are responsible for his death accountable and to change how inmates are treated at the jail.
'Just basic training in having compassion for others would be a great start. But adding more staff is critical too,' they said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
'A heavy burden:' On Ben Askren's new life and what to expect after a double lung transplant
Ben Askren headed home from the hospital this week with a new set of lungs and a second chance at life. Or, depending on how you think about it, maybe it's more like a fourth or fifth chance, since that's about how many times he estimated he'd already died while in the hospital battling severe pneumonia linked to a staph infection. 'Amy, how close was I to dying?' Askren asked his wife in the car ride home while posting an update for his social-media followers. 'Too close,' she told him. 'A few times.' As recently as early June, Amy Askren had told those same social-media followers she was 'praying for a miracle.' Her husband — a retired MMA fighter, two-time NCAA national champion wrestler and former Olympian — was unconscious and hooked up to machines, including a ventilator and an ECMO device (extracorporeal membrane oxygenation — essentially a form of life support). The prognosis was dire. Askren needed a double lung transplant. If he didn't get it, he'd die. All over those combat sports sections of the internet, the support came in the form of prayers and fundraisers. Former opponent Jake Paul and UFC CEO Dana White, among others, contributed financial support. And then in late June, the miracle came. Amy Askren announced June 30 her husband had received a double lung transplant. 'We are forever thankful to the donor and his family,' she wrote on Facebook. 'This is the beginning of a new lifestyle for Ben, but every new day he has is a gift. It still doesn't feel real that he was walking around completely healthy just 5 weeks ago. So much can change so quickly.' But the challenges for Askren are still just beginning, according to Dr. Kirlos Haroun, a physician at Johns Hopkins Hospital in Baltimore. As both a fight fan and a doctor, Haroun followed Askren's story closely. He's seen similar cases in his work as an emergency room physician and Johns Hopkins faculty member, he said, so he knows the risks lung transplant patients face. 'I've dealt with a lot of really acute lung injury, and I've dealt with transplant patients. The double lung transplant is this really complex last resort for very, very severe lung injuries,' Haroun told Uncrowned. "It's the only transplant that is exposed to the air with every breath, so it's exposed to the world at every moment. You combine that with pretty strong drugs, somebody who's immunocompromised, and your risk for infection every day is incredibly high.' There are two main threats for any lung transplant patient, according to Haroun. The first is that, as with any transplant, the body may reject the new organ. Medication can lower this risk — and transplant patients will need to remain on that medication for their entire lives — but it does so by suppressing the body's natural immune system. That leaves patients at higher risk of infection, but also vulnerable to diseases like cancer, Haroun said. 'Whenever I see a transplant patient in my ER, and they come in with a cough, the thought is always opportunistic infections. There are viruses, there are fungal infections, and then there's really bad drug-resistant bacteria,' Haroun said. 'Ben's going to be taking some very heavy immunosuppressive drugs just to let the transplant work. I mean, people with transplants, they live their lives, but there is always this concern. Anyone you're around can expose you to something. "I would be cautious about him even entering a gym, let alone rolling and wrestling just because of the infection risk. A skin abrasion can lead to a severe reinfection that can be life-threatening, and I think that's a really, really emotionally and mentally difficult thing beyond the physical risks he has.' One person who understands both the physical and emotional challenges is Jeffrey Pinard, who underwent a double lung transplant a little less than two years ago. Pinard was diagnosed with cystic fibrosis as a child, he said, so medical risks and challenges have essentially always been a part of his life. After dealing with multiple infections that affected his lungs, he was finally placed on the lung transplant list while in his early 50s. 'I was on the wait list about eight months,' Pinard said. 'I had to be taken off the wait list five different times because there was a question about going through with the transplant since I had such drug-resistant bugs in me. "No one told me this beforehand, thankfully, but I only had a few weeks to live when I finally got my lungs. When the surgeon cut into my lungs to start taking them out, they exploded. That was something they had never seen before. There was just so much infection packed in there.' Pinard knew more than most what to expect. As a college student, he'd studied genetics and microbiology at the University of Michigan. He was even an undergrad assistant on the research team led by geneticist Francis Collins who, in conjunction with Lap-Chee Tsui and his team at the Hospital for Sick Children in Toronto, first isolated the gene for cystic fibrosis. Because of his experience with that disease, Pinard said, he was already well-accustomed to the sometimes drastic steps needed to avoid infection after the lung transplant. 'Everyone who has a cold is a threat to you,' Pinard said. 'Like, a mortal threat. Big crowds, things like that, you have to change your behavior so that you minimize your risk as much as possible. "The first year post-transplant is the hardest. That's when you're going to have the highest levels of steroids, prednisone and some of the other anti-rejection drugs. As you improve and your body gets used to the new lungs, then they can start tapering those off and then there will be a little bit less risk. But of course, that never goes away and you really have to balance the threat of infections with the threat of rejection.' But after reading about Askren, Pinard said, he does see reason for optimism. He was a relatively young man and healthy lifelong athlete with no major known comorbidities prior to the illness that necessitated the transplant. At the same time, there are more than just the physical adjustments to consider after such a dramatic life change. 'This transplant is so different for every single person,' Pinard said. 'I know people who've had it and were doing great within a month. I'm close to two years and I'm still struggling. But it's also about perspective. The year or so before my transplant, I was basically living on the couch, which isn't much of a life. Even getting up to make myself a peanut butter and jelly sandwich felt like an enormous task that took so much effort. So now, when I can do something like empty the dishwasher and it doesn't take every ounce of effort I have? It feels phenomenal. It makes me feel like a million dollars. But I don't know how he'll feel about that, having been an MMA fighter and an athlete. Being so strong and then having the rug pulled out from under you, it can be a shock.' There's also the looming question of mortality. Survival rates for lung transplant patients have steadily improved over the years, but Pinard noted the five-year survival rate for this procedure is still just a little over 50%. Recent statistics suggest slightly more than one-third of double lung transplant recipients are now making it past the 10-year mark. Some have lived 20 years or more after the procedure, but they are the exceptions. 'Psychologically, it is kind of a heavy burden. If you look at the statistics, 10% of double lung transplant patients die every year,' Pinard said. 'You can't help but see that you've got an expiration date.' Still, Pinard said, he sees more reason for optimism than pessimism in Askren's situation. His support system, his experience pushing through physical and emotional challenges, all the same things that made him successful as an athlete, these should serve Askren well in his new life, Pinard said. But make no mistake, he added, it is a new and different life awaiting the former fighter as he recovers from the transplant surgery. 'It will get better. That's the thing I'd say to Ben right now, is it will get better,' Pinard said. 'I wish I'd known that more. At first, every day can be very difficult to get through. You're learning how to breathe again with new lungs. You're learning how to get up and walk again. Some people are in a lot more pain than others after the surgery. But it will get better, so don't set deadlines for yourself or get disappointed if it takes longer than you expect. If it takes a year to get back to a stable place, that's fine.' As Askren lay in the hospital awaiting his transplant, he noted in one social-media post it was difficult at times to ward off negative feelings. Here he was, a man who hadn't smoked, had always tried to take care of his health, and now he needed new lungs just to have a chance at survival. 'I will not feel bad for myself,' Askren said at one point. Earlier this week, as he headed home, his message was one of gratitude. 'I said this already in one of my videos, but the support you guys gave me, whether it was sending a GoFundMe, whether it was helping my kids and wife get through it — I had friends from all over the country come to visit and hang out for a couple of days — it meant so much,' Askren said in one video. 'It was so great to just have all this support and all the love, and hopefully I'm not in this situation again for a really, really, really long time. I plan on living a while.'
Yahoo
26 minutes ago
- Yahoo
The 3 Things That Matter for Eli Lilly Now
Key Points Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral GLP-1 candidate will soon report key phase 3 results in weight management. The drugmaker's shares look expensive, but the premium is justified given Lilly's prospects. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong clinical and regulatory progress, as well as robust financial results, the drugmaker has routinely impressed Wall Street. Lilly has experienced a slowdown this year, and its shares have underperformed broader equities. Still, the company could turn things around and return to its market-beating ways, especially if it can execute effectively on several fronts. Let's discuss three critical areas of its business to pay close attention to right now. 1. Tirzepatide's progress It has now been more than three years since the U.S. Food and Drug Administration (FDA) first approved tirzepatide, the medicine Eli Lilly markets as Mounjaro for treating diabetes and as Zepbound for weight management. The two brands have been generating mouthwatering sales. Each racked up billions of dollars in revenue last quarter. Mounjaro and Zepbound will continue to be crucial to Eli Lilly's progress. Here are two key things to watch. First, how quickly are their sales continuing to grow? Analysts will be closely monitoring these numbers for the foreseeable future. Image source: Getty Images. Second, will they earn label expansions? Tirzepatide has already aced other phase 3 studies, such as in cutting the risk of diabetes in patients who were overweight (or obese) and prediabetic. Regulatory authorities are now reviewing it in helping prevent heart failure in obese patients. Tirzepatide is being investigated in late-stage trials as a potential treatment for psoriasis and psoriatic arthritis in combination with other medicines. It's also being tested in mid-stage studies in metabolic dysfunction-associated steatohepatitis (MASH). So the therapy could earn many more label expansions, which will help boost its already fast-growing sales. It's a good idea to monitor Lilly's developments related to this drug. 2. Orforglipron's weight management results In April, Eli Lilly posted strong phase 3 results for its next-gen GLP-1 medicine, orforglipron, in diabetes patients. Orforglipron is a particularly important pipeline candidate to follow, because it could be one of the first oral GLP-1 therapies to hit the market. Some patients don't like needles and would vastly prefer a daily oral option over the current subcutaneously administered options. And while Lilly's recent phase 3 win for orforglipron in diabetes was significant, investors will be especially interested in the medicine's performance in weight management.
Yahoo
26 minutes ago
- Yahoo
Pura Scents recalling more than 850,000 diffusers as magnet issue may cause ingestion hazard
Pura Scents is recalling more than 850,000 diffusers because some magnets may detach and cause a possible ingestion hazard to children. The company is recalling about 851,400 Pura 4 Smart Home Fragrance Diffusers with detachable covers. It said an additional 1,100 were sold in Canada. Pura Scents said that the magnets on the inside cover of the product can detach, posing an ingestion hazard to children. When high-powered magnets are swallowed, the ingested magnets can attract each other, or other metal objects, and become lodged in the digestive system. This can result in perforations, twisting or blockage of the intestines, infection, blood poisoning and death. The company has received three reports of magnets detaching from the cover. No injuries have been reported. The diffusers were sold at Target, Scheels and other stores nationwide from August 2023 through May 2025 for about $50. They were also sold online through Pura's website, as well as online at Amazon, Target and Scheels. Pura Scents is offering a free replacement cover. Consumers are advised to immediately dispose of the existing detachable cover and to keep the diffusers out of the reach of children and pets. To receive the free replacement cover, individuals may contact Pura Scents at 855-394-5292 from 9 a.m. to 5 p.m. MT Monday through Friday. The company can also be emailed at replacement@ Consumers may also visit the company's website and click on 'Recall' at the bottom of the page for more information. Michelle Chapman, The Associated Press Sign in to access your portfolio
